Trial Profile
Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2016
Price :
$35
*
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis; Encephalitis virus infections
- Focus Adverse reactions; Registrational
- Sponsors Pfizer